Drug delivery in overcoming the blood–brain barrier: role of nasal mucosal grafting
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The blood-brain barrier (BBB) plays a fundamental role in protecting and maintaining the homeostasis of the brain. For this reason, drug delivery to the brain is much more difficult than that to other compartments of the body. In order to bypass or cross the BBB, many strategies have been developed: invasive techniques, such as temporary disruption of the BBB or direct intraventricular and intracerebral administration of the drug, as well as noninvasive techniques. Preliminary results, reported in the large number of studies on the potential strategies for brain delivery, are encouraging, but it is far too early to draw any conclusion about the actual use of these therapeutic approaches. Among the most recent, but still pioneering, approaches related to the nasal mucosa properties, the permeabilization of the BBB via nasal mucosal engrafting can offer new potential opportunities. It should be emphasized that this surgical procedure is quite invasive, but the implication for patient outcome needs to be compared to the gold standard of direct intracranial injection, and evaluated whilst keeping in mind that central nervous system diseases and lysosomal storage diseases are chronic and severely debilitating and that up to now no therapy seems to be completely successful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development, maintenance and disruption of the blood-brain barrier
Obermeier, B., Daneman, R., & Ransohoff, R. M. (2013) · Nature Medicine · doi:10.1038/nm.3407 · Cited by 2,452 · cited 1×
“19,20 It should also be pointed out that alterations in the barrier, as in the blood–brain tumor barrier (BBTB), often form an increased obstacle in CNS therapy by preventing the delivery of potentially effective therapeutic agents.”
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Tau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806 · cited 1×
“5 For this reason, disorders of the CNS represent one of the largest areas of unsatisfied medical needs, with about 2 billion people affected worldwide and many pharma companies moving away from such fields of innovative research because of the high risk of failure associated with CNS medicines,…”
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2923 · Cited by 674
Intranasal Drug Delivery: How, Why and What For?
Pires, A., Fortuna, A., Alves, G., & Falcão, A. (2009) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3nc79 · Cited by 641
Nasal mucociliary clearance as a factor in nasal drug delivery
Marttin, E., Schipper, N. G. M., Verhoef, J. C., & Merkus, F. W. H. M. (1998) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00059-8 · Cited by 469 · cited 1×
“57 This chirurgical procedure can be an efficient method to assure drug localization in the CNS, especially in the case of HMW drugs, such as enzymes that are widely used in the treatment of lysosomal storage diseases.”
Lysosomal storage diseases: from pathophysiology to therapy
Parenti, G., Andria, G., & Ballabio, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-122313-085916 · Cited by 404 · cited 1×
“59 Moreover, alterations in the BBB are likely involved in LSDs as well as in all neurodegenerative diseases.”
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387 · cited 1×
“29 In recent times, much attention has been given to nano-technology in many areas because of its significant potential for the successful treatment of severe diseases such as cancer and neurological diseases.”
Direct access of drugs to the human brain after intranasal drug administration?
Merkus, P., Guchelaar, H.-J., Bosch, D. A., & Merkus, F. W. H. M. (2003) · Neurology · doi:10.1212/01.wnl.0000067993.60735.77 · Cited by 81 · cited 2×
“Direct intranasal transport is not always well established, and controversial results were obtained when similar substances were administered, and sometimes, even opposite results have been reported after nasal delivery to the CSF.(46,47) A few years ago, Merkus and van den Berg,(48) reviewing more than 100 papers, re…”
Tosi, G., Vilella, A., Chhabra, R., Schmeisser, M. J., Boeckers, T. M., Ruozi, B., Vandelli, M. A., Forni, F., Zoli, M., & Grabrucker, A. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.01.004 · Cited by 56
Cited by
Extracellular vesicles: novel promising delivery systems for therapy of brain diseases.
Rufino-Ramos, D., Albuquerque, P. R., Carmona, V., Perfeito, R., Nobre, R. J., & Pereira de Almeida, L. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.07.001 · Cited by 418
Kohman, R. E., Kunjapur, A. M., Hysolli, E., Wang, Y., & Church, G. M. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201707976 · Cited by 33
Ogata, K., Ataka, K., Suzuki, H., Yagi, T., Okawa, A., Fukumoto, T., Zhang, B., Nakata, M., Yada, T., & Asakawa, A. (2020) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2020/5418586 · Cited by 29
Metadata
- Authors
- Marianecci, C., Rinaldi, F., Hanieh, P. N., Di Marzio, L., Paolino, D., & Carafa, M.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-01
- Volume
- Volume11
- Pages
- 325-335
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W2580826593
- Cited by
- 40
- References
- 16
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.